DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the presentation of positive data from a Phase 2 trial that evaluated the safety, clinical response and immune response of AGS-003 treatment in newly diagnosed patients with metastatic renal cell carcinoma (mRCC). The data were discussed March 7 in a poster presentation at the ASCO Genitourinary Cancers Symposium. AGS-003 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique tumor burden. According to results from the study, AGS-003 induced a tumor-specific immune response, performed better than interferon-a on a measure of progression-free survival, and was well tolerated.
